SCHEMBL3106487

SCHEMBL3106487

O=c1[nH]c(=O)c2c(F)cccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.50
PARP1 P09874 3/20 0.48
KDM4E B2RXH2 2/20 0.48
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
DAO P14920 2/20 0.43
DDO Q99489 1/20 0.43
PGR P06401 1/20 0.39
FFAR1 O14842 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
TYMP P19971 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
MAPT P10636 2/20 0.38
PDE3B Q13370 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567841 1.00 FEN1 (0.50) FEN1PARP1KDM4ECA12CA9
SCHEMBL24575981 0.81 FEN1 (0.47) FEN1PARP1KDM4ECA12CA9
SCHEMBL9128769 0.76 FEN1 (0.50) FEN1PARP1KDM4ECA12CA9
SCHEMBL7030237 0.76 DAO (0.41) PARP1KDM4ECA12CA9DAO
SCHEMBL6645136 0.76 KDM4E (0.48) PARP1KDM4ECA12CA9TYMP
SCHEMBL3125353 0.76 PARP1 (0.49) PARP1KDM4ECA12CA9DAO
SCHEMBL16529364 0.76 KDM4E (0.48) PARP1KDM4ECA12CA9GRIN2D
SCHEMBL12832866 0.76 KDM4E (0.48) PARP1KDM4ECA12CA9GRIN2D
SCHEMBL4515077 0.76 PARP1 (0.48) PARP1KDM4ECA12CA9GRIN2D
SCHEMBL8144559 0.76 IMPDH2 (0.50) PARP1KDM4ECA12CA9DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2022-06-14 US claimed
US-20250270212-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES PADARN THERAPEUTICS INC (US) 2025-08-28 US disclosed
EP-4416151-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES Padarn Therapeutics, Inc. (US) 2024-08-21 EP disclosed
US-20230399316-A1 CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2023-12-14 US disclosed
US-20230399316-A1 CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2023-12-14 US disclosed
WO-2023064164-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES PADARN THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064164-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES PADARN THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2022-06-14 US disclosed
WO-2022100577-A1 CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-05-19 WO disclosed
EP-3438096-B1 MANUFACTURING PROCESS FOR 1-(ARYLMETHYL) QUINAZOLINE-2,4 (1H, 3H)-DIONE IMPACT THERAPEUTICS INC (CN) 2020-12-02 EP disclosed
US-20040242568-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2004-12-02 US disclosed
US-20040242566-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2004-12-02 US disclosed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 WO disclosed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 WO disclosed
EP-0878468-B1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL CO (JP) 2003-03-19 EP disclosed
EP-0775697-B1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL CO (JP) 2003-02-12 EP disclosed
US-5994542-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-11-30 US disclosed
EP-0878468-A1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-18 EP disclosed
US-5756738-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-05-26 US disclosed
EP-0775697-A1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242566-A1 Dipeptidyl peptidase inhibitors DPP9, DPP3, DPP4 FEN1 962/4885PARP1 2025/4885KDM4E 2254/4885
US-20040242568-A1 Dipeptidyl peptidase inhibitors DPP9, DPP4, DPP3 FEN1 1883/4885PARP1 1840/4885KDM4E 2122/4885
US-20230399316-A1 CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF NT5C, DCUN1D5, PYM1 FEN1 799/4885PARP1 133/4885KDM4E 1122/4885
US-20250270212-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES WEE1, WEE2, PARP1 FEN1 55/4885PARP1 3/4885KDM4E 2398/4885
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof PARP1, PARP11, PARP3 FEN1 182/4885PARP1 1/4885KDM4E 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.